Testing SHR-2173 for Generalized Myasthenia Gravis
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests a new drug called SHR-2173 to help people with generalized myasthenia gravis (a condition where muscles weaken because the immune system blocks communication between nerves and muscles). The drug is designed to work with treatments you're already taking to improve muscle strength and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of generalized myasthenia gravis (gMG) with moderate to severe symptoms
- Blood test showing antibodies against AChR or MuSK (proteins involved in nerve-muscle communication)
- Currently taking stable standard-of-care myasthenia gravis medications
- Able to receive rescue treatments like IVIg or PLEX if needed during the trial
- No recent myasthenic crisis (severe muscle weakness episode) in the past 3 months
- No active cancer, serious infections, or certain immune system disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called B007 for people with generalized myasthenia gravis who have specific antibodies and moderate to severe muscle weakness. It aims to see if the drug can improve daily activities and reduce symptoms.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an investigational drug called IMVT-1402 to see if it improves symptoms in people with generalized myasthenia gravis (gMG). If you have mild to severe gMG and are looking for new treatment options, this study may be a fit.
This trial tests a new drug called HN2301 for patients with generalized myasthenia gravis (a disease where the immune system weakens muscles) who have not responded well to standard treatments. The goal is to see if HN2301 can safely improve muscle strength and daily function.
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.
Hear when a new Generalized Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.